Measurement of the serum level of Elabela for the early detection of acute kidney injury in hospitalized Iraqi COVID-19 patients
DOI:
https://doi.org/10.32007/jfacmedbagdad.6431928Abstract
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is caused coronavirus disease
2019 (COVID-19) affecting people worldwide. The angiotensin converting enzyme2 (ACE2) represents a
receptor of SARS-CoV-2 on the infected host cell. Apelin or its receptor agonists suppress the production of
angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) and is characterized by a protective effect
against SARS-CoV-2.
Objective: The study aims to assess the serum level of Elabela biomarker as an early detector for Acute
Kidney Injury (AKI) in patients with COVID-19.
Cases and Methods: This is a case-control study which included 45 hospitalized adult patients in multiple
centers (public hospitals) receiving COVID-19 cases in Baghdad. These cases had a positive real-time or
reverse transcription polymerase chain reaction (RT-PCR) of nasal/oropharyngeal swabs. Excluded from the
study were those with a negative PCR and comorbidities and 43 apparently healthy adult subjects as controls.
The age range of the cases and controls was (20 to 60) years
Result: There are no a statistically significant differences between the two groups in terms of age and gender
distribution. Statistically significant differences were found in terms of eGFR, S. Creatinine, D. dimer,
NEU×103
/µL, LYM×103
/µL and ELA biomarker. Significant negative correlations were found between
Elabela with D. dimer and NEU×103
/µL, and between eGFR with S. creatinine, D. Dimer, and NUT×103
/µL.
Conclusion: The Elabela biomarker can be used for the early detection of acute kidney injury in COVID-19
patients.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 maha hassan Gadhi, Eman S. Saleh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
For all articles published in Journal of the Faculty of Medicine Baghdad, copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY NC 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work, while ensuring that the authors receive proper rights.